Thymidine kinase 1: A proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients

Oncology Reports

Volumn 15, Issue 2, 2006, Pages 455-461

  Zhang, Jie ^a   Jia, Quanan ^a   Zou, Shan ^a   Zhang, Pingan ^a   Zhang, Xiaobing ^a   Skog, Sven ^b   Luo, Pengcheng ^a   Zhang, Wei ^a   He, Qimin ^b  

^a WUHAN UNIVERSITY   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti TK1 IgY chicken antibody; Bladder carcinoma; Recurrence; Serum thymidine kinase 1; Thymidine kinase 1

Indexed keywords

THYMIDINE KINASE; THYMIDINE KINASE 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; BLOOD; CANCER STAGING; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOBLOTTING; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; THYMIDINE KINASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33744501889     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.2.455     Document Type: Article

References (40)

1. Cook AM, Huddart RA, Jay G, Norman A, Dearnaley DP and Horwich A: The utility of tumor markers in assessing the response to chemotherapy in advanced bladder cancer. Br J Cancer 82: 1952-1957, 2000. (Pubitemid 30326456)
2. Izes JK, Dyer MW, Callum MG, Bankes P, Libertino JA and Caffrey JA: Ca 125 as a marker of tumor activity in advanced urothelial malignancy. J Urol 165: 190-193, 2001.
3. Moreno Sierra J, Maestro de las Casas ML, Ortega Heredia MD, Blanco Jimenez E, Hermida Gutierrez J and Resel Estevez L: Serum and tissue quantification of tissue polypeptide antigen (TPA) in transitional cell carcinoma of the bladder. Arch Esp Urol 47: 979-984, 1997.
4. Ecke TH, Lenk SV, Schlechte HH and Loening SA: Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. Anticancer Res 23: 957-962, 2003. (Pubitemid 36750902)
5. Sanchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megias J, Mira A and Soria F: New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 45: 1944-1953, 1999. (Pubitemid 29522002)
6. Pariente JL, Bordenave L, Jacob F, Gobinet A, Leger F, Ferriere JM and Le Guillou M: Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J Urol 163: 1116-1119, 2000. (Pubitemid 30169374)
7. Menendez V, Galan JA, Fernandez-Suarez A, Lopez S, Alcover J, Calpena R and Filella X: Prognostic value of tissue-polypeptide specific antigen (TPS) in bladder cancer. Anticancer Res 22: 3713-3716, 2002. (Pubitemid 36132854)
8. Ramazan Sekeroglu M, Aydin S, Dulger H, Yilmaz Y, Bayrakli H and Noyan T: Diagnostic value of cytokeratin-18 as a tumor marker in bladder cancer. Clin Biochem 35: 327-331, 2002. (Pubitemid 34804905)
9. Mady EA: Cytokeratins as serum markers in Egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS. Int J Biol Markers 16: 130-135, 2001.
10. Kelloniemi E, Rintala E, Finne P, Stenman UH and Finn Bladder Group: Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 62: 249-253, 2003.
11. Simms MS, Hughes OD, Limb M, Price MR and Bishop MC: MUC1 mucin as a tumor marker in bladder cancer. BJU Int 84: 350-352, 1999. (Pubitemid 29376187)
12. Sanchez-Carbayo M: Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. Clin Chem 49: 23-31, 2003.
13. Valenzuela MT, Galisteo R, Zuluaga A, Villalobos M, Nunez MI, Oliver FJ and Ruiz de Almodovar JM: Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol 42: 622-628, 2002. (Pubitemid 35462344)
14. Mao YR, Wu JP, Wang N, He JX, Wu CJ, He Q and Skog S: Comparison study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Inv 20: 922-931, 2002. (Pubitemid 35315926)
15. Wu CJ, Yang RJ, Zhou J, Bao S, Zou L, Mao YR and He Q: Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Method 277: 157-169, 2003. (Pubitemid 36694382)
16. He Q, Mao RY and Wu JP: Immunohistochemical expression of thymidine kinase in patients with breast carcinoma. In: Immunohistochemical and In Situ Hybridisation of Human Carcinomas. Hayat MA (ed). Elsevier Science/Academic, San Diego, CA, pp463-470, 2004.
17. He Q, Mao YR, Wu JP, Decker C, Merza M, Wang N, Eriksson S, Castro J and Skog S: Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 25: 945-953, 2004.
18. Mao YR, Wang N, Wu JP, Hu LX, Wu CJ, He Q and Skog S: A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res 20: 4815-4820, 2001.
19. Kuroiwa N, Nakayama M, Fukuda T, Fukui H, Ohwada H, Hiwasa T and Fujimura S: Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibody raised against recombinant human thymidine kinase, J Immunol Methods 253: 1-11, 2001. (Pubitemid 32522510)
20. Wang N, He Q, Skog S, Eriksson S and Tribukait B: Investigation on cell proliferation with a new antibody against thymidine kinase 1. Anal Cell Pathol 23: 11-19, 2001. (Pubitemid 34014656)
21. He Q, Zou L, Zhang P, Liu J, Skog S and Fonander T: The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody, Int J Biol Markers 15: 139-146, 2000. (Pubitemid 30389361)
22. Zou L, Zhang PG, Zou S, Li Y and He Q: The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers 17: 135-140, 2002. (Pubitemid 34873800)
23. Broet P, Romain S, Daver A, Ricolleau G, Quillen V, Rallet A, Asselain B, Martin PM and Spyratos F: Thymidine kinase as a proliferative marker: Clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 19: 2778-2787, 2001. (Pubitemid 32538185)
24. Mizutani Y, Wada H, Yoshida O, Fukushima M, Kamoi K and Miki T: Prognostic significance of thymidine kinase activity in bladder carcinoma. Cancer 95: 2120-2125, 2002. (Pubitemid 35253373)
25. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M: AJCC cancer stage. Manual. 5th edition. Springer, New York, pp167-178, 1997.
26. Wilson GD: Assessment of human tumour proliferation using bromodeoxyuridine - current status. Acta Oncol 30: 903-910, 1991.
27. Tribukait B: Flow cytometry in assessing the clinical aggressiveness of genito-urinary neoplasms. World J Urol 5: 108-122, 1987.
28. Hall PA and Woods AL: Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Tissue Kinet 25: 505-522, 1990.
29. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2002. (Pubitemid 30054364)
30. Elsevier SM, Kucherlapati RS, Nichols EA, Creagan RP, Giles RE, Ruddle FH, Willecke K and McDougall JK: Assignment of the gene for galactokinase to human chromosome 17 and its regional localization to band q21-22. Nature 251: 633-636, 1974.
31. Willecke K, Teber T, Kucherlapati RS and Ruddle FH: Human mitochondrial thymidine kinase is coded for by a gene on chromosome 16 of the nucleus. Somatic Cell Genet 3: 237-245, 1977. (Pubitemid 8160573)
32. Munch-Petersen B, Cloos L, Jensen HK and Tyrsted G: Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35: 69-89, 1995.
33. Eriksson S, Munch-Petersen B, Johansson K and Eklund H: Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 59: 1327-1346, 2002.
34. He Q, Skog S, Wang N, Eriksson S and Tribukait B: Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol 70: 117-124, 1996. (Pubitemid 26177210)
35. Ke PY and Chang ZF: Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 24: 514-526, 2004.
36. Gronowich JS, Hagberg H, Källander CFR and Simonsson B: The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47: 487-495, 1983. (Pubitemid 13089615)
37. Karlström AR, Neumuller M, Gronowitz JS and Kallander CF: Molecular forms in human serum of enzymes synthesizing DNA precursors and DNA. Mol Cell Biochem 92: 23-35, 1990. (Pubitemid 20044372)
38. Fujiwara H, Arima N, Ohtsubo H, Matsumoto T, Kukita T, Kawada H, Imaizumi R, Ozaki A, Matsushita K and Tei C: Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia. Am J Hematol 71: 80-84, 2002.
39. Hallek M, Touitou Y, Levi F, Mechkouri M, Bogdan A, Bailleul F, Senekowitsch R and Emmerich B: Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer. Clin Chim Acta 267: 155-166, 1997. (Pubitemid 28021727)
40. Li HX, Zhang S, Lei DS, Wang XQ, Skog S and He Q: Serum thymidine kinase 1 (STK1) is a prognostic and monitoring factor in patients with non-small-cell lung cancer. Oncol Rep 13: 145-149, 2005.